Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of ADR-002K in ischemic cardiomyopathy patients undergoing CABG
jRCT2053190103Phase 1Active, not recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-002K in ischaemic cardiomyopathy (ICM), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoints: Adverse events and safety evaluation related to ADR-002K, Exploratory efficacy of ADR-002K and 1 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
ADR-002K
03
Conditions
ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on jRCT2053190103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053190103.